|
All Releases
 |
Achillion Announces Private Placement of $50 Million
Aug 18, 2010
|
13.2 KB |
|
| |
Aug 18, 2010 (GlobeNewswire via COMTEX News Network) --
Proceeds to Fund Expanding Pipeline of HCV Candidates
Clinical Update Conference Call Scheduled for August 19th at 10:00 a.m.
ET
NEW HAVEN, Conn., Aug. 18, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN...
|
|
Achillion Reports Second Quarter and Six Month Financial Results
Aug 13, 2010
|
15.2 KB |
|
| |
NEW HAVEN, Conn., Aug 13, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and six months ended June 30, 2010. For the second quarter of 20...
|
|
Achillion Pharmaceuticals Announces Nomination of NS5A Inhibitor as a Lead Clinical Candidate for Treatment of HCV
Jul 22, 2010
|
11.9 KB |
|
| |
NEW HAVEN, Conn., Jul 22, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) i...
|
|
Achillion to Present at Upcoming Conference
Jun 3, 2010
|
9.1 KB |
|
| |
NEW HAVEN, Conn., Jun 3, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Milind S. Deshpande, Executive Vice President and Chief Scientific Officer, will give a cor...
|
|
Achillion Announces Positive Once-Daily Dosing Results With ACH-1625 to Treat Hepatitis C
May 11, 2010
|
17.0 KB |
|
| |
May 11, 2010 (GlobeNewswire via COMTEX News Network) --
Once-Daily Dose Achieves 3.81 log10 Viral Load Reduction With Continued
Safety and Tolerability
Conference Call Begins Wednesday, May 12 at 1:15 p.m. Eastern Time
NEW HAVEN, Conn., May 11, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc...
|
|
Achillion Reports First Quarter Financial Results
May 10, 2010
|
13.4 KB |
|
| |
NEW HAVEN, Conn., May 10, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the ...
|
|
Achillion Presents Data From Studies of ACH-1625 in Hepatitis C at the EASL International Liver Congress
Apr 15, 2010
|
16.5 KB |
|
| |
NEW HAVEN, Conn., Apr 15, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today presented data from the Company's ongoing Phase 1 clinical trial of ACH-1625 to treat hepatitis C (HCV) at the European Association for the Study of the Liver's (EASL) International Liver Congress taking place at the Reed Me...
|
|
Achillion Announces Award of NIH Grant to Study Unique Antibacterial Compound Series
Mar 18, 2010
|
11.2 KB |
|
| |
NEW HAVEN, Conn., Mar 18, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has received a Phase 1 Small Business Innovation Research Grant (SBIR) from the Nationa...
|
|
Achillion Reports 2009 Fourth Quarter and Year-End Financial Results
Mar 12, 2010
|
15.3 KB |
|
| |
NEW HAVEN, Conn., Mar 12, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2009.
For the three mon...
|
|
Achillion to Present at Upcoming Investor Conferences
Mar 5, 2010
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Mar 5, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will be presenting a company overview at the u...
|
|
Achillion Announces Positive 96-Week Data for Elvucitabine at the 17th Annual Conference on Retroviruses and Opportunistic Infections
Feb 17, 2010
|
13.0 KB |
|
| |
NEW HAVEN, Conn., Feb 17, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the presentation of additional positive safety and efficacy results from its Phase 2 trial stud...
|
|
Achillion to Present at 12th Annual BIO CEO and Investor Conference
Feb 8, 2010
|
9.1 KB |
|
| |
NEW HAVEN, Conn., Feb 8, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will present a corporate and clinical update a...
|
|
Achillion Announces Closing of Underwriters' Over-Allotment Option
Feb 2, 2010
|
9.9 KB |
|
| |
NEW HAVEN, Conn., Feb 2, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it closed the sale of an additional 1,541,250 shares of its common stock in connection with the exercise of...
|
|
Achillion Announces License Agreement for Elvucitabine Development in China
Feb 1, 2010
|
14.0 KB |
|
| |
NEW HAVEN, Conn., Feb 1, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the execution of a license agreement for elvucitabine, the Company's nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) infection and human immunodeficiency virus (HI...
|
|
Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program
Jan 28, 2010
|
13.0 KB |
|
| |
NEW HAVEN, Conn., Jan 28, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of a lead clinical candidate in its third proprietary program against hepatitis C infection. The candidate, ACH-2684, demonstrates excellent potency in the low pico-molar range, as well as good pharm...
|
|
Achillion to Host Corporate and Clinical Update Conference Call on Monday, February 1, 2010
Jan 25, 2010
|
12.2 KB |
|
| |
NEW HAVEN, Conn., Jan 25, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Achillion's President and Chief Executive Officer, will lead the Com...
|
|
Achillion Prices $21.4 Million Public Offering of Common Stock
Jan 22, 2010
|
11.5 KB |
|
| |
NEW HAVEN, Conn., Jan 22, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it has priced a firm commitment underwritten public offering of 10,275,000 shares of its common stock at p...
|
|
Achillion Announces Proposed Public Offering of Common Stock
Jan 21, 2010
|
11.4 KB |
|
| |
NEW HAVEN, Conn., Jan 21, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it intends to offer, subject to market, regulatory and other conditions, shares of its common stock in an ...
|
|
Achillion Announces Additional Positive Phase 1b Data With ACH-1625 to Treat Hepatitis C
Jan 11, 2010
|
13.8 KB |
|
| |
NEW HAVEN, Conn., Jan 11, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported additional preliminary data from its on-going phase 1b clinical trial of ACH-1625 which demonstrated that the second dosing cohort receiving treatment with ACH-1625 achieved a mean 4.25 log10 reduction in HCV RNA af...
|
|
Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C
Dec 15, 2009
|
15.1 KB |
|
| |
NEW HAVEN, Conn., Dec 15, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported proof of concept data from the preliminary results of its phase 1b clinical trial of ACH-1625, demonstrating that treatment with ACH-1625 achieved a mean 3.94 log10 reduction in HCV RNA after five-day monotherapy, w...
|
|
|
= add release to Briefcase |